Income Statement

BRIDGEBIO PHARMA, INC.

BBIO
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY Dec 31, 2019 2019 FY
Revenue
502.08 221.90 9.30 77.65 69.72 8.25 40.56
Cost of Revenue
20.96 3.88 2.45 - 2.74 - -
Gross Profit
481.11 218.02 6.86 77.65 66.98 8.25 40.56
Operating Expenses
983.18 795.39 606.30 542.65 643.23 482.73 306.80
Research & Development
451.95 506.46 455.71 399.46 451.02 337.05 209.95
Selling, General & Administrative
531.23 288.93 150.59 143.19 192.21 145.68 94.35
Other Operating Expenses
- - - - - - -
Operating Income
-502.06 -577.37 -599.44 -465.00 -576.25 -474.48 -266.24
Non-Operating Income
-209.09 50.78 -45.88 27.55 -9.82 -31.01 -22.35
Interest Income
19.85 17.25 18.04 7.54 1.13 4.02 8.92
Interest Expense
44.50 54.80 81.29 80.44 46.78 36.66 8.77
Other Non-Op Income / Expense
-35.10 -31.18 17.37 -7.50 35.82 1.63 0.20
Income Before Tax
-732.50 -542.19 - - - 505.49 288.59
Income Tax Expense
0.44 1.15 - - - - -
Non-Controlling Interest
-8.01 -7.59 -10.05 -3.47 -23.92 -56.76 -28.00
Net Income
-732.94 -543.35 -653.25 -484.65 -586.45 -505.49 -288.59
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY Dec 31, 2019 2019 FY
Depreciation & Amortization
- - - - - - -
EBITDA
-496.63 -571.29 -592.95 -458.23 -570.41 -474.48 -266.24
Earnings Per Share (Basic)
-3.78 -2.88 -3.95 -3.26 - - -
Diluted EPS
-3.78 -2.88 -3.95 -3.26 - - -
Weighted Average Shares
191.53 186.08 162.79 147.47 - - -
Diluted Weighted Avg Shares
191.53 186.08 162.79 147.47 - - -
Comprehensive Income
-724.93 -535.79 -642.84 -481.38 -562.86 -448.79 -260.33